72,234 articles
HOXA9
HOXA9 (homeobox A9), a posterior HOX-cluster transcription factor gene at 7p15, regulates hematopoietic progenitors; its overexpression, MLL/NUP98-driven dysregulation, MEIS1 partnership, and methylation status mark poor prognosis in AML.
HOXB13
HOXB13 (homeobox B13) is a human homeobox transcription factor gene on chromosome 17q21.32, active in prostate development. Its G84E founder mutation (rs138213197) raises hereditary prostate cancer risk three- to four-fold, mainly in European-ancestry men.
Hoyeraal-Hreidarsson syndrome
Hoyeraal-Hreidarsson syndrome, or HHS, is a rare, severe X-linked variant of dyskeratosis congenita, a telomere biology disorder, marked by cerebellar hypoplasia, immune deficiency, and aplastic anemia.
HPAF-II
HPAF-II, also written HPAF-2, is a well-differentiated human pancreatic ductal adenocarcinoma cell line established from the ascites of a 44-year-old man, cataloged as ATCC CRL-1997.
HPB-ALL
HPB-ALL (HPB/ALL, CVCL_1820) is a human T-cell acute lymphoblastic leukemia cell line established in 1973 from a 14-year-old Japanese boy, CD4+CD8+, NOTCH1-mutant, TLX3-expressing, distributed as DSMZ ACC 483 and RIKEN RCB1935.
HPC, Cord Blood
HPC, Cord Blood is the FDA proper name for allogeneic umbilical cord blood hematopoietic progenitor cell products (Hemacord, Ducord, REGENECYTE) licensed for unrelated-donor transplantation to reconstitute blood and immunity in hematopoietic disorders.
HPV self-collection
HPV self-collection is a cervical cancer screening method in which a person collects their own vaginal sample, tested for 14 high-risk HPV types as primary screening.
HPV self-sampling
HPV self-sampling is a cervical cancer screening method in which a person collects their own vaginal specimen for high-risk HPV DNA testing, raising participation among people who decline clinician-collected sampling.
HPV testing
HPV testing, also known as the HPV DNA test, detects high-risk human papillomavirus DNA or mRNA in cervical or vaginal samples to screen for cervical cancer, the WHO-recommended primary screening method.
HPV vaccine
HPV vaccine (Gardasil 9, Cervarix, Cecolin): prophylactic vaccine against human papillomavirus, first approved 2006, preventing cervical and other cancers; CDC routine at 11-12, WHO supports 1- or 2-dose schedules.
HR-cSCC study
HR-cSCC (NCT05246228) is a prospective observational Italian study of 42 patients with high-risk cutaneous squamous cell carcinoma, testing whether post-radiotherapy lymphopenia (ALC below 500 cells/mL) predicts disease-free survival.
HRAS
HRAS (Harvey rat sarcoma viral oncogene homolog), a proto-oncogene on 11p15.5, was the first human oncogene cloned (1982, T24 bladder carcinoma). Germline activating mutations cause Costello syndrome; somatic HRAS mutations are rare in cancer.
Hrdayarnava Rasa
Hridayarnava Rasa (Hridayarnava Ras), a Kharaliya Rasayana herbo-mineral Ayurvedic formulation of purified mercury, sulphur, and Tamra Bhasma with Triphala and Kakamachi, indicated for Hridroga, especially Kaphaja heart disease.
HRDC domain
HRDC domain (helicase and RNaseD C-terminal domain), ~80-amino-acid five-helix bundle at the C-terminus of RecQ helicases such as BLM and WRN and of RNase D; modulates DNA binding, substrate specificity, and unwinding rates.
Hrdyavirecana Leha
Hṛdyavirecana leha (AFI000314) is an Ayurvedic avaleha confection from the Aṣṭāṅgahṛdaya, made with honey, sugar, trivṛt (Operculina turpethum), and aromatics; AFI dose 12 g, used for constipation, fever, thirst, and as a cardiotonic.
HRS-1167 (PARP1 inhibitor)
HRS-1167 (M9466) is Jiangsu Hengrui's oral, second-generation selective PARP1 inhibitor with DNA trapping activity, licensed to Merck KGaA in 2023 for EUR160 million and later discontinued by Merck; distinct from Merck & Co's MK-1167 Alzheimer's drug.
HRS-1596
HRS-1596 (Hengrui Pharma) is a phase 1-ready oral GLP-1R/GIPR dual agonist for once-weekly dosing in obesity and type 2 diabetes, licensed to Novo Nordisk on 29 September 2026 for up to $2.6 billion excluding Greater China.
HRS-4729
HRS-4729 (KAI-4729) is Hengrui's once-weekly injectable GLP-1/GIP/glucagon tri-agonist peptide for obesity, licensed to Kailera outside Greater China; its Phase 1 trial showed 16.0% weight loss at 12 weeks.
HRS-5346
HRS-5346 (MK-7262) is Hengrui's oral small-molecule lipoprotein(a) inhibitor, licensed to MSD outside Greater China for $200 million upfront; Phase 2 in China cut Lp(a) up to 86% at 12 weeks.
HRS-7249
HRS-7249: GalNAc-conjugated APOC3-targeting siRNA injection by Hengrui's Shanghai Tuojie unit, in phase 2 China trials for hyperlipidemia and severe hypertriglyceridemia; phase 1 TG cuts of 62-75%.
HRS-7535
HRS-7535 is Jiangsu Hengrui's once-daily oral small-molecule (nonpeptide) GLP-1 receptor agonist for type 2 diabetes and weight management; phase 2 trials showed HbA1c cuts up to 1.57% and weight loss up to 9.36%, with a China NDA accepted in 2026.
HRS-9821, PDE3/PDE4 dual inhibitor (COPD)
HRS-9821 (GSK-licensed Hengrui compound) is an investigational inhaled dual PDE3/PDE4 inhibitor for COPD add-on maintenance therapy, in phase II trials in China and licensed to GSK worldwide ex-Greater China in July 2025.
HRS9531 (瑞普泊肽)
HRS9531 (瑞普泊肽, ribupatide, KAI-9531) is Jiangsu Hengrui's once-weekly dual GLP-1/GIP receptor agonist for obesity and type 2 diabetes; phase 3 showed 19.2% weight loss at 48 weeks, with NDAs filed in China.
Hs 294T
Hs 294T (HS294T, CVCL_0331, ATCC HTB-140) is a human metastatic melanoma cell line from a lymph node metastasis, BRAF V600E and TERT promoter mutant, used in drug-response and resistance research.
Hs 578T
Hs 578T (ATCC HTB-126, CVCL_0332) is a human triple-negative, basal-like breast cancer cell line derived in 1977 from a 74-year-old patient, syngeneic with Hs 578Bst, carrying an H-ras codon 12 mutation and a hypotriploid karyotype.
Hs 675.T
Hs 675.T (Hs675T, CVCL_0836, ATCC CRL-7400) is a human colon-derived fibroblast cell line, male Caucasian donor, originally misclassified as colorectal carcinoma; doubling time 6-7 days, DMEM culture, documented STR profile.
Hs 700T
Hs 700T (HS700T, CVCL_0858, ATCC HTB-147) is a human pancreatic ductal adenocarcinoma cell line from a 61-year-old man's pelvic metastasis, hypertetraploid, TP53 p.Arg249Met, doubling time 4-5 days.
Hs 746.T
Hs 746.T (Hs746T, CVCL_0333, ATCC HTB-135) is a human diffuse-type gastric adenocarcinoma cell line established in 1973 from a skeletal muscle metastasis, MET-amplified with a c-Met exon 14 splice mutation, used in MET-inhibitor drug testing.
Hs 766T
Hs 766T (Hs-766T, HS766T, CVCL_0334, ATCC HTB-134) is a human pancreatic adenocarcinoma cell line isolated in 1973 from a lymph node metastasis, carrying homozygous KRAS Q61H and SMAD4 deletion, gemcitabine-resistant, with a normoid gene expression profile.
HS-10353
HS-10353 is Hansoh Pharmaceutical's investigational oral GABA-A receptor positive allosteric modulator, a zuranolone-like small molecule in Phase 2 trials for major depressive and postpartum depression, with Phase 1 efficacy and safety data published.